Compounded Semaglutide Legal Status 2026: What the FDA Actually Says

The legal status of compounded semaglutide has become one of the most complex and contentious issues in pharmaceutical law. Millions of patients rely on affordable compounded versions, while Novo Nordisk -- the maker of Ozempic and Wegovy -- has pursued aggressive legal strategies to restrict compounding. Here is what the FDA actually says, what the courts have decided, and what it means for your prescription.

The Legal Framework for Compounding

Pharmaceutical compounding in the United States is governed primarily by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Quality and Security Act (DQSA) of 2013. Two key sections define the legal pathways:

Section 503A: Traditional Compounding Pharmacies

Section 503A pharmacies compound medications based on individual prescriptions from licensed prescribers. They are state-licensed, not FDA-registered, and operate under state board of pharmacy oversight. They can compound medications that are commercially available under certain conditions, including when a prescriber determines a compounded product is necessary for a specific patient.

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities are FDA-registered and inspected. They can compound larger batches without individual prescriptions and sell to healthcare facilities. They must follow current Good Manufacturing Practice (cGMP) standards. The FDA maintains a list of drugs that 503B facilities can compound, with the shortage list playing a critical role.

The Drug Shortage List: The Linchpin

The FDA drug shortage list has been the primary legal basis for widespread semaglutide compounding. When a drug is listed as being in shortage, compounding pharmacies have broader authority to produce compounded versions. The shortage status has fluctuated:

What the FDA Actually Says (2026)

The FDA's position on compounded semaglutide has been nuanced and sometimes criticized for ambiguity. Here are the key points from FDA communications:

• Compounding is legal under appropriate conditions. The FDA acknowledges that compounding serves an important role in patient care when conducted by qualified pharmacies following proper standards.
• Not all compounded semaglutide is the same as brand-name. The FDA emphasizes that compounded products are not FDA-approved and have not undergone the same testing for safety, efficacy, and quality as Ozempic and Wegovy.
• Quality concerns exist. FDA inspections of some compounding pharmacies have revealed quality issues, including incorrect potency, contamination, and sterility failures.
• Patients should use licensed sources. The FDA urges patients to obtain compounded semaglutide only from state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities.
• Warning letters issued to bad actors. The FDA has sent warning letters to pharmacies selling semaglutide without prescriptions, making unsubstantiated claims, or using substandard ingredients.

The Semaglutide Salt Form Debate

A significant legal argument centers on the chemical form of semaglutide used in compounding. Brand-name Ozempic and Wegovy contain semaglutide base, while many compounding pharmacies use semaglutide sodium salt. Novo Nordisk has argued these are not the same molecule, while compounders contend the sodium salt is a legitimate pharmaceutical equivalent.

Courts have reached different conclusions on this issue, and the FDA has weighed in with guidance that remains subject to interpretation. The practical impact for patients is that the specific form of semaglutide in your compounded medication may affect its legal categorization differently depending on your jurisdiction.

State-by-State Variations

Because 503A pharmacies are primarily regulated at the state level, compounding rules vary significantly by state. Some states have:

• Enacted legislation specifically protecting patient access to compounded GLP-1 medications
• Implemented stricter quality standards for compounding pharmacies
• Required compounding pharmacies to register with additional state agencies
• Created patient disclosure requirements about the non-FDA-approved status of compounded medications

Your state's specific regulations affect what your pharmacy can legally produce and how they can market it. Check with your state board of pharmacy for the most current rules in your area.

What This Means for Patients

Looking Ahead: What May Change

Several developments could shift the legal landscape in the coming months:

• Ongoing litigation outcomes: Novo Nordisk's lawsuits against compounders could result in landmark rulings
• FDA regulatory changes: New guidance documents could clarify or restrict compounding authority
• Congressional action: Several bills related to compounding access have been introduced
• Generic semaglutide: The eventual availability of generic semaglutide could reduce the need for compounding
• New GLP-1 medications: Approval of additional GLP-1 drugs may expand options for patients

Key Takeaways

• Compounded semaglutide remains legal in 2026 through licensed pharmacies, but the landscape is evolving
• The FDA drug shortage list status is the primary legal driver for 503B compounding
• 503A pharmacies can compound based on individual prescriptions regardless of shortage status
• Verify your pharmacy is properly licensed or FDA-registered
• Always obtain compounded semaglutide with a valid prescription
• Stay informed about legal changes that could affect availability
• Have a contingency plan in case your source becomes unavailable